Zura Bio

Zura Bio is a clinical-stage biopharmaceutical company focused on creating therapies for autoimmune and inflammatory diseases. Incorporated in 2022, the company became a publicly traded entity on the Nasdaq in March 2023 following a reverse merger with JATT Acquisition Corp, a special purpose acquisition company (SPAC). This business combination provided approximately $65 million in gross cash proceeds to advance its research and development initiatives. The company was founded by Dr. Someit Sidhu, who also served as the CEO of JATT Acquisition Corp. Dr. Sidhu has a background in the life sciences industry, co-founding Pathios Therapeutics and holding CEO positions at Akaza Bioscience and Izana Bioscience. In April 2024, Robert Lisicki, an executive with 30 years of experience in the biopharmaceutical industry, took over as CEO.

The company's business model is centered on the clinical development and eventual commercialization of its portfolio of drug candidates. Zura Bio's strategy involves a dual-pathway approach, developing antibodies that target multiple biological mechanisms simultaneously to potentially enhance treatment efficacy for complex autoimmune diseases. The company's pipeline consists of three assets that have completed initial Phase 1/1b studies. Its lead product candidate, tibulizumab (ZB-106), is a dual-antagonist antibody that neutralizes both IL-17A and B-cell activating factor (BAFF). Tibulizumab is currently in global Phase 2 clinical trials for treating hidradenitis suppurativa (HS), a chronic inflammatory skin disease, and systemic sclerosis (SSc), a rare autoimmune disorder. Topline data for the HS and SSc trials are anticipated in the third and fourth quarters of 2026, respectively.

Other assets in the pipeline include crebankitug (ZB-168), an antibody targeting the IL-7 receptor alpha chain, and torudokimab (ZB-880), which neutralizes IL-33. These candidates are being evaluated for various immune-mediated diseases. Zura Bio in-licensed crebankitug from Pfizer and both tibulizumab and torudokimab from Eli Lilly and Company. The company's revenue is not yet established as its products are still in development, and it currently operates at a net loss, funding its operations through cash reserves from its public listing and financing activities. As of June 2025, the company reported having enough cash to fund planned operations through 2027.

Keywords: Zura Bio, clinical-stage biotechnology, autoimmune diseases, inflammatory disorders, dual-pathway antibodies, tibulizumab, hidradenitis suppurativa, systemic sclerosis, crebankitug, torudokimab, IL-17A inhibitor, BAFF inhibitor, IL-7 receptor, IL-33, biopharmaceutical, immunology, reverse merger, SPAC, JATT Acquisition Corp, Dr. Someit Sidhu, Robert Lisicki, Phase 2 clinical trials